Immune Globulin Intravenous (Human)

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
65	原発性免疫不全症候群	14

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

trials per page:

Showing 1 to 10 of 14 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04346108 (ClinicalTrials.gov)	August 11, 2020	10/4/2020	A Study of Immune GlobulinSubcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants Wi ...	A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and ...	Primary Immunodeficiency Diseases (PID)	Biological: Immune Globulin Intravenous(IGIV);Biological: Immune GlobulinSubcutaneous, 20% Solution ...	Baxalta now part of Shire	NULL	Completed	2 Years	N/A	All	17	Phase 3	Japan
2	NCT02269163 (ClinicalTrials.gov)	January 26, 2016	16/10/2014	Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%	A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic B ...	Primary Immunodeficiency	Biological: Immune Globulin Intravenous;Biological: Prometic's Immune Globulin Intravenous 10%	Prometic Biotherapeutics, Inc.	Atlantic Research Group	Completed	2 Years	80 Years	All	82	Phase 3	United States
3	NCT01218438 (ClinicalTrials.gov)	January 2013	8/10/2010	Phase 2/3 Study of IGSC, 20% in PIDD	A Clinical Study of Immune GlobulinSubcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation ...	Primary Immunodeficiency Diseases (PID)	Biological: Immune Globulin Intravenous (Human), 10% Solution;Drug: Immune GlobulinSubcutaneous (Hum ...	Baxalta now part of Shire	NULL	Completed	2 Years	N/A	All	86	Phase 2/Phase 3	United States;Canada
4	NCT01406470 (ClinicalTrials.gov)	September 2011	26/7/2011	Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficien ...	An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Eval ...	Immunologic Deficiency Syndrome	Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™	Green Cross Corporation	Atlantic Research Group	Completed	2 Years	70 Years	Both	45	Phase 3	United States;Canada
5	NCT01412385 (ClinicalTrials.gov)	June 20, 2011	8/8/2011	Immune Globulin Subcutaenous (Human), 20%	A Clinical Study of Immune GlobulinSubcutaneous (Human)(IGSC), 20% for the Evaluation of Efficacy, S ...	Primary Immunodeficiency Diseases (PID)	Biological: Immune GlobulinSubcutaneous (Human), 20%;Biological: Immune Globulin Intravenous (Human) ...	Baxalta now part of Shire	NULL	Completed	2 Years	N/A	All	55	Phase 2/Phase 3	Austria;Germany;Hungary;Sweden;United Kingdom
6	NCT00814320 (ClinicalTrials.gov)	December 18, 2008	23/12/2008	Gammagard Liquid and rHuPH20 in PID	Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (G ...	Primary Immunodeficiency Diseases (PID)	Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)	Baxalta now part of Shire	NULL	Completed	2 Years	N/A	All	89	Phase 3	United States;Canada
7	NCT00634569 (ClinicalTrials.gov)	May 2008	5/3/2008	Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects	Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for ...	Primary Immune Deficiency Disease	Biological: Flebogamma 5% DIF	Instituto Grifols, S.A.	NULL	Completed	2 Years	16 Years	All	24	Phase 4	United States
8	NCT00546871 (ClinicalTrials.gov)	October 3, 2007	18/10/2007	Comparison of Intravenousand Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (P ...	Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human)10% (IGIV, 10%) Ad ...	Primary Immunodeficiency Diseases (PID)	Drug: Immune Globulin Intravenous (Human), 10%	Baxalta now part of Shire	NULL	Completed	24 Months	N/A	All	49	Phase 2/Phase 3	United States
9	NCT00389324 (ClinicalTrials.gov)	November 2006	17/10/2006	A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immuno ...	An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics and Safety of Subcut ...	Immunologic Deficiency Syndrome	Biological: Immune Globulin Intravenous (Human)	Grifols Therapeutics Inc.	NULL	Completed	13 Years	75 Years	All	35	Phase 2	United States;Canada
10	NCT00220766 (ClinicalTrials.gov)	August 2002	13/9/2005	Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients	IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients	Immunologic Deficiency Syndrome;Agammaglobulinemia;Severe Combined Immunodeficiency;Wiskott-Aldrich ...	Drug: Immune Globulin Intravenous[Human], 10% Caprylate/Chromatography Purified;Drug: Dextrose, 5% i ...	Grifols Therapeutics Inc.	NULL	Completed	18 Years	75 Years	Both	100	Phase 3	United States;Canada

First Previous1 2Next Last